|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
MET FISH
MessageProbes: MET (7q31) | Centromere 7
Disease(s): Multiple solid tumor cancers including lung (NSCLC), gastric, esophageal, endometrial
Disease(s): Multiple solid tumor cancers including lung (NSCLC), gastric, esophageal, endometrial
Test Code
LAB6015
CPT Codes
88377x1 manual or 88374x1 automated.
Preferred Specimen
•Bone marrow aspirate: N/A
•Peripheral blood: N/A
•Fresh, unfixed tissue: N/A
•Fluids: N/A
•Paraffin block: Send paraffin block. Also send circled H&E slide for tech-only (required).
•Cut slides: H&E slide (required) plus 4 unstained slides cut at 4-5 microns. Circle H&E slide for tech-only.
•Peripheral blood: N/A
•Fresh, unfixed tissue: N/A
•Fluids: N/A
•Paraffin block: Send paraffin block. Also send circled H&E slide for tech-only (required).
•Cut slides: H&E slide (required) plus 4 unstained slides cut at 4-5 microns. Circle H&E slide for tech-only.
Instructions
Use cold pack for transport. Make sure cold pack is not in direct contact with specimen.
Methodology
FISH
Report Available
4 days
Clinical Significance
MET gene amplification, as detected by FISH, is one mechanism of MET overexpression. MET amplifications are detected in 3-7% of non-small cell lung cancer (NSCLC) and associated with resistance to EGFR inhibitors and shorter survival in this disease. MET amplifications are also detected in a wide variety of other solid tumors including gastric (up to 10%), esophageal (4%), and endometrial tumors. Clinical trials have demonstrated activity of MET inhibitors against numerous solid tumors such as lung, breast, melanoma, liver, prostate, renal, and ovarian, including tumor reduction in NSCLC and breast cancer patients who had developed resistance to EGFR inhibitors.
Performing Laboratory
Neogenomics Laboratories
